These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14533451)

  • 1. Cancer pharmacogenomics: SNPs, chips, and the individual patient.
    McLeod HL; Yu J
    Cancer Invest; 2003; 21(4):630-40. PubMed ID: 14533451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy.
    Evans WE
    Ther Drug Monit; 2004 Apr; 26(2):186-91. PubMed ID: 15228163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.
    Krynetski EY; Evans WE
    Pharm Res; 1999 Mar; 16(3):342-9. PubMed ID: 10213363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer pharmacogenomics: current and future applications.
    Watters JW; McLeod HL
    Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.
    McLeod HL; Siva C
    Pharmacogenomics; 2002 Jan; 3(1):89-98. PubMed ID: 11966406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia].
    Ma XL; Zhu P; Wu MY; Li ZG; Hu YM
    Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):929-33. PubMed ID: 14723818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug methylation in cancer therapy: lessons from the TPMT polymorphism.
    Krynetski E; Evans WE
    Oncogene; 2003 Oct; 22(47):7403-13. PubMed ID: 14576848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
    Evans WE; Hon YY; Bomgaars L; Coutre S; Holdsworth M; Janco R; Kalwinsky D; Keller F; Khatib Z; Margolin J; Murray J; Quinn J; Ravindranath Y; Ritchey K; Roberts W; Rogers ZR; Schiff D; Steuber C; Tucci F; Kornegay N; Krynetski EY; Relling MV
    J Clin Oncol; 2001 Apr; 19(8):2293-301. PubMed ID: 11304783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
    Albayrak M; Konyssova U; Kaya Z; Gursel T; Guntekin S; Percin EF; Kocak U
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1155-9. PubMed ID: 21400026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics: unlocking the human genome for better drug therapy.
    McLeod HL; Evans WE
    Annu Rev Pharmacol Toxicol; 2001; 41():101-21. PubMed ID: 11264452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics: the inherited basis for interindividual differences in drug response.
    Evans WE; Johnson JA
    Annu Rev Genomics Hum Genet; 2001; 2():9-39. PubMed ID: 11701642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics: translating functional genomics into rational therapeutics.
    Evans WE; Relling MV
    Science; 1999 Oct; 286(5439):487-91. PubMed ID: 10521338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic differences in pharmacogenetically relevant genes.
    Engen RM; Marsh S; Van Booven DJ; McLeod HL
    Curr Drug Targets; 2006 Dec; 7(12):1641-8. PubMed ID: 17168839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of cancer chemotherapy-induced toxicity.
    Miller CR; McLeod HL
    J Support Oncol; 2007 Jan; 5(1):9-14. PubMed ID: 17265780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.